Phase 3 Myeloma Trial, Recruiting (NCT07319897)

Phase 3 Myeloma Trial, Recruiting NCT07319897 Sponsor: Peking University First Hospital Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT07319897 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have suspected or previously diagnosed multiple myeloma (a type of blood cancer) and are already scheduled to have a bone marrow sample or tissue biopsy taken within two weeks — this includes people being checked for the first time or being monitored for disease changes or return of illness
People who have been confirmed to have active, symptomatic multiple myeloma
People who are able to understand the study and are willing to sign a written consent form agreeing to take part
People who are able to follow the study's procedures and requirements
People whose general health and ability to carry out daily activities meets a certain minimum level, as rated by a standard medical scale (confirm with trial site)

Who may not be able to join:

People who are pregnant or currently breastfeeding
People who are not able to understand the study procedures or are unable to follow the requirements of the study protocol
People who have any other health condition that, in the opinion of the trial doctor, could interfere with taking part in the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lei Kang, M.D, Ph.D, Peking University First Hospital

Phone: 86+13811486428

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07319897

Sponsor: Peking University First Hospital

Phase: Phase 3

Status: Recruiting

Condition: Myeloma

Trial contact: 86+13811486428

More information: https://clinicaltrials.gov/study/NCT07319897

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have suspected or previously diagnosed multiple myeloma (a type of blood cancer) and are already scheduled to have a bone marrow sample or tissue biopsy taken within two weeks — this includes people being checked for the first time or being monitored for disease changes or return of illness
People who have been confirmed to have active, symptomatic multiple myeloma
People who are able to understand the study and are willing to sign a written consent form agreeing to take part
People who are able to follow the study's procedures and requirements
People whose general health and ability to carry out daily activities meets a certain minimum level, as rated by a standard medical scale (confirm with trial site)

Who may not be able to join:

People who are pregnant or currently breastfeeding
People who are not able to understand the study procedures or are unable to follow the requirements of the study protocol
People who have any other health condition that, in the opinion of the trial doctor, could interfere with taking part in the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Peking University First Hospital

Registry

ClinicalTrials.gov

Start date

25 December 2025

Est. completion

30 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Diagnostic performance of 68Ga-BCMA PET/CT; Safety of BCMA-targeted radiotracer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov